STERIS Reports Impressive Financial Results for Q2 of Fiscal 2026
STERIS plc (NYSE: STE) recently announced strong financial results for the second quarter of fiscal 2026, highlighting notable growth in revenue and earnings. The company saw total revenue from continuing operations rise by 10%, escalating to $1.5 billion compared to the previous year's $1.3 billion. Additionally, constant currency organic revenue growth from continuing operations reached an impressive 9%, showcasing the company’s robust performance despite various market challenges.
Positive Earnings Performance
During the second quarter, STERIS reported earnings per diluted share of $1.94 from continuing operations, which was a significant increase from $1.51 in the same quarter of fiscal 2025. Adjusted earnings per share rose to $2.47, up from $2.14 from the previous year. Dan Carestio, President and CEO of STERIS, expressed satisfaction with these results, noting that they exceeded expectations, and highlighted improvements in profit margins during this period.
Healthcare Segment Performance
The Healthcare segment demonstrated considerable growth, with reported revenue rising 9% to $1,033.8 million from $944.2 million a year earlier. This growth was driven by a 13% increase in service revenue, a 10% rise in consumable revenue, and a 4% growth in capital equipment revenue. The operating income for the Healthcare segment also saw an increase to $259.5 million, up from $228.0 million, reflecting efficiencies and productivity gained from previous restructuring efforts.
Applied Sterilization Technologies Growth
Steris's Applied Sterilization Technologies (AST) segment achieved a 10% revenue increase to $281.5 million. This growth was mainly due to a 13% rise in service revenue, despite a notable decrease in capital equipment revenue. Operating income for the segment increased to $127.6 million compared to $109.9 million, attributed to favorable pricing and improved revenue mix.
Life Sciences Segment Revenue Boost
The Life Sciences segment also experienced significant growth with a revenue increase of 13%, reaching $145.0 million. This segment benefited from a notable 39% boost in capital equipment revenue, along with growth in service and consumable revenue. Operating income climbed to $59.9 million, reflecting strong demand and volume, which offset costs associated with tariffs and inflation.
Strong Cash Flow and Financial Outlook
Throughout the first half of fiscal 2026, net cash provided by operations reached $707.8 million, a substantial increase compared to $554.4 million in the previous year. Free cash flow for this period totaled $527.7 million, a significant improvement from $344.5 million last year. Due to these positive trends, STERIS has increased its outlook for fiscal 2026, now anticipating a revenue growth of 8-9% from continuing operations.
Company's Updated Fiscal 2026 Guidance
The forecast for total revenue from continuing operations for fiscal 2026 remains stable, while expectations for organic revenue growth have been adjusted upward to a projected 7-8%. The company now anticipates adjusted earnings per diluted share to range between $10.15 and $10.30, an increase from previous estimates. STERIS is also addressing the financial implications of tariffs, projecting a pre-tax profit impact of approximately $45 million.
Future of STERIS
Moving forward, STERIS is set to maintain its focus on innovation and quality in addressing healthcare needs globally. The company continues to provide valuable infection prevention solutions, aiming to enhance patient care and safety. STERIS’s commitment to operational excellence and market adaptability positions it strategically for continued growth in an evolving healthcare landscape.
Frequently Asked Questions
What were STERIS's revenue figures for Q2 fiscal 2026?
STERIS reported total revenue of $1.5 billion in the second quarter, a 10% increase from the previous year.
How did the Healthcare segment perform in Q2?
The Healthcare segment grew by 9%, generating $1,033.8 million in revenue, supported by increased service and consumable sales.
What is the outlook for STERIS in fiscal 2026?
The company expects revenue growth of 8-9% and adjusted earnings per share to be in the range of $10.15 to $10.30.
How much cash flow did STERIS generate in the first half of fiscal 2026?
STERIS generated $707.8 million in net cash from operations during the first half of fiscal 2026.
Who can I contact for more information about STERIS?
For inquiries, please contact Julie Winter, Vice President of Investor Relations, via email at Julie_Winter@steris.com.
